Design Therapeutics (DSGN) EBIT Margin (2020)
Historic EBIT Margin for Design Therapeutics (DSGN) over the last 1 years, with Q4 2020 value amounting to 11700.0%.
- Design Therapeutics' EBIT Margin changed N/A to 11700.0% in Q4 2020 from the same period last year, while for Dec 2020 it was 3685.84%, marking a year-over-year change of. This contributed to the annual value of 3685.84% for FY2020, which is N/A changed from last year.
- Design Therapeutics' EBIT Margin amounted to 11700.0% in Q4 2020.
- In the past 5 years, Design Therapeutics' EBIT Margin registered a high of 438.73% during Q1 2020, and its lowest value of 11915.0% during Q3 2020.